Cleared Traditional

K212095 - SurGuard3 Safety Hypodermic Needle

K212095 is the FDA 510(k) clearance for SurGuard3 Safety Hypodermic Needle by Terumo Europe N.V.. It is a Class 2 General Hospital device (product code FMI) cleared through the Traditional 510(k) pathway after a 412-day FDA review.

K212095 · Terumo Europe N.V. · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2022
Decision
412d
Days
Class 2
Risk

K212095 is an FDA 510(k) clearance for the SurGuard3 Safety Hypodermic Needle. Classified as Needle, Hypodermic, Single Lumen (product code FMI), Class II - Special Controls.

Submitted by Terumo Europe N.V. (Leuven, BE). The FDA issued a Cleared decision on August 22, 2022 after a review of 412 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5570 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind General Hospital submissions.

View all Terumo Europe N.V. devices

Submission Details

510(k) Number K212095 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 06, 2021
Decision Date August 22, 2022
Days to Decision 412 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
283d slower than avg
Panel avg: 129d · This submission: 412d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code FMI Needle, Hypodermic, Single Lumen
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5570
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - FMI Needle, Hypodermic, Single Lumen

All 235
Devices cleared under the same product code (FMI) and FDA review panel - the closest regulatory comparables to K212095.
Sterile Safety Hypodermic Needles for Single Use
K221080 · Sichuan Prius Biotechnology Co., Ltd. · Oct 2022
Promisemed X-Safety Pen Needle
K220129 · Promisemed Hangzhou Meditech Co., Ltd. · Sep 2022
Disposable Medical Safety Hypodermic Needle
K220603 · Hantech Medical Device Co., Ltd. · Aug 2022
Insulin Pen Needle
K221176 · Tianjin Huahong Technology Co., Ltd. · Jul 2022
BD Pen Needle
K213478 · Becton, Dickinson and Company · Jun 2022
MEDOJECT fine Pen Needles
K220614 · Chirana T. Injecta · Jun 2022